drugset / Trial / NCT00651235

A Randomized, Open-label, LOSARTAN Therapy on the Progression of Aortic Root Dilation in Patients With Marfan Syndrome

NCT00651235

Phase 2 Unknown 44 enrolled National Taiwan University Hospital
RandomizedFactorialOpen-labelPrevention

Summary

To assess the efficacy of angiotensin II receptor blocker, Losartan, to prevent progressive dilation of aortic root in patients with Marfan syndrome.

Timeline

Start
2007-02
Primary completion
2011-02
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Losartan Other / unclassified 50 mg
Subject Losartan Other / unclassified 100 mg
Comparator Atenolol Other / unclassified 2 mg/kg
Comparator Atenolol Other / unclassified 50 mg
Comparator Atenolol Other / unclassified 150 mg
Comparator Propranolol Small molecule 1 mg/kg
Comparator Propranolol Small molecule 2 mg/kg
Comparator Propranolol Small molecule 20 mg
Comparator Propranolol Small molecule 150 mg

Indications